23andMe Holding Co. (ME) Quick Ratio (Acid-Test): 0.70
Is 23andMe Holding Co.’s quick ratio (acid-test) high or low?
23andMe Holding Co.'s quick ratio (acid-test) of 0.70 is 69% below its 5-year average of 2.23, near the low end of its 5-year range (0.70–3.86).
As of Monday, June 15, 2026. 45.53% below its 12-month average of 1.29.
ME Quick Ratio (Acid-Test) Chart
ME Average Quick Ratio (Acid-Test) Chart
ME Current vs Average Quick Ratio (Acid-Test) Chart
ME Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
0.70
QUICK RATIO (ACID-TEST) AVG TTM
1.29
QUICK RATIO (ACID-TEST) AVG 3Y
2.30
QUICK RATIO (ACID-TEST) AVG 5Y
2.23
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-45.53%
CURRENT VS 3Y AVG
-69.60%
CURRENT VS 5Y AVG
-68.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ME Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | 0.70 | 1.29 | 2.30 | 2.23 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.02B | 1.03 | 0.89 | 0.95 | 0.97 |
| Hims & Hers Health, Inc. (HIMS)vs › | $5.98B | 1.61 | 1.56 | 2.48 | 3.39 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 4.19 | 4.52 | 4.42 | 3.69 |
| Tempus AI, Inc. (TEM)vs › | $8.35B | 3.00 | 2.58 | 2.23 | 3.05 |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | 1.02 | 1.07 | 1.10 | 1.11 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.37 | 0.33 | 0.35 | 0.35 |
| Baxter International Inc. (BAX)vs › | $10.77B | 1.56 | 1.31 | 1.23 | 1.40 |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 1.24 | 1.17 | 1.11 | 1.16 |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 1.13 | 1.13 | 0.99 | 0.98 |
Liquidity Comparison
Quick Ratio
0.70
Excludes inventory
Current Ratio
0.83
Includes inventory
23andMe Holding Co. Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for 23andMe Holding Co. (ME)?
- The quick ratio (acid-test) for ME stock is 0.70.
- Is 23andMe Holding Co.'s quick ratio (acid-test) high or low?
- 23andMe Holding Co.'s quick ratio (acid-test) of 0.70 is 69% below its 5-year average of 2.23, near the low end of its 5-year range (0.70–3.86).
- What is the TTM average quick ratio (acid-test) for 23andMe Holding Co. (ME)?
- The TTM average quick ratio (acid-test) for ME stock is 1.29.
- What is the 3Y average quick ratio (acid-test) for 23andMe Holding Co. (ME)?
- The 3Y average quick ratio (acid-test) for ME stock is 2.30.
- What is the 5Y average quick ratio (acid-test) for 23andMe Holding Co. (ME)?
- The 5Y average quick ratio (acid-test) for ME stock is 2.23.
23andMe Holding Co. Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-03-31 | 0.70 |
| 2024-03-31 | 1.87 |
| 2023-03-31 | 2.78 |
| 2022-03-31 | 3.86 |
| 2021-03-31 | 2.53 |
| 2020-03-31 | 1.66 |
| 2019-03-31 | 2.68 |
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage